Shigella included in Open Lab calls

After two pilot calls with drug discovery for Shigellosis as eligible for funding, TCOLF will include this disease as a permanent research area in scope.

Rates of resistance to Shigella have evolved rapidly over last 10 years, reaching 45 to 100% to certain compounds including fluoroquinolones and other first-line agents. Shigella-specific treatments could facilitate quick intervention to avoid progression to severe diseases and avoid the related mortality and long term side effects.
The key research areas are described in the “Submit your project proposal” section.